Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Opioid Prescribing Guidelines Will Be More Template Than Commandment

Executive Summary

Commissioner Gottlieb says US FDA does not intend to force physicians to adhere to opioid prescribing guidelines being developed by National Academies of Sciences, Engineering, and Medicine.
Advertisement

Related Content

Cost Concerns May Hinder Naloxone Co-Prescribing Ideas
Recent And Upcoming FDA Advisory Committee Meetings
Gottlieb Renews Call For New Opioid Review Paradigm As Democrats Prepare For House Control
US FDA May Largely Avoid House Democrats' Investigation Agenda
Opioid Blister-Pack Mandate Tops Gottlieb's Agenda With New Authority
Opioid REMS Increases Nearly Six-Fold As US FDA Adds Immediate-Release Products
Opioid, NME, And Generic Drugs Changes Plotted In US FDA's 2018 Policy Roadmap
Opioid Packaging Standards Could Emerge From Dosage Guidelines in Labeling

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS124248

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel